AllPennyStocks.com Small Cap Rips On Multiple Bullish Analyst Outlooks

Small Cap Rips On Multiple Bullish Analyst Outlooks

Small Cap Rips On Multiple Bullish Analyst Outlooks By: Tomas Ronolski - AllPennyStocks.com News

Wednesday, June 18, 2025

A Massachusetts-based biotech company stole the show during Wednesdays session after it was disclosed that Chardan Capital maintained its buy rating on the stock, and maintained their $13 price target. Mizuho and Needham also maintained/reiterated outperform and buy ratings, respectively.

Traders obviously like what they saw from the handful of analyst reports as they snatched up shares of Immuneering Corporation (Nasdaq:IMRX), pushing the small cap up to $2.63/share (+44.51%) at the early session high. 

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies.


Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Travel Tech Play Soars on a Bet on China's Inbound Tourism Reopening
A Nickel District in Northern Ontario Just Reached a Scale That Invites Sudbury Comparisons
When Gold Sets Records, the Lowest-Cost Ounces Win the Rerating
Most Popular
{{ index + 1 }}


Back to Top